Lrrk2-mediated Neuronal Toxicity
Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration were identified. The presently disclosed subject matter establishes that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for treating Parkinson's disease.
Patents:WO 2,011,057,204
Inventor(s):
LEE BYOUNG DAE [US]; DAWSON TED M [US]; DAWSON VALINA L [US]; WEST ANDREW B [US]
Type of Offer:
Licensing
« More Medical Patents